[Insulin pump therapy and continuous glucose monitoring].
Diabetestechnologie (Update 2023).
AID
Artificial pancreas
CGM
Closed-loop
Diabetes technology
Insulin pump therapy
Mobile apps
Telemedicine
Threshold-suspension
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
16
02
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
This Guideline represents the recommendations of the Austrian Diabetes Association (ÖDG) on the use of diabetes technology (insulin pump therapy; continuous glucose monitoring, CGM; hybrid closed-loop systems, HCL; diabetes apps) and access to these technological innovations for people with diabetes mellitus based on current scientific evidence. Diese Leitlinie repräsentiert die Empfehlungen der Österreichischen Diabetes Gesellschaft (ÖDG) zur Nutzung von Diabetes-Technologie (Insulinpumpentherapie; kontinuierliche Glukosemesssysteme, CGM; Hybrid Closed Loop Systeme, HCL; Automated Insulin Delivery Systeme, AID, Diabetes-Apps) und den Zugang zu diesen technologischen Innovationen für Menschen mit Diabetes mellitus. Die Leitlinie wurde basierend auf aktueller wissenschaftlicher Evidenz erstellt.
Autres résumés
Type: Publisher
(ger)
Diese Leitlinie repräsentiert die Empfehlungen der Österreichischen Diabetes Gesellschaft (ÖDG) zur Nutzung von Diabetes-Technologie (Insulinpumpentherapie; kontinuierliche Glukosemesssysteme, CGM; Hybrid Closed Loop Systeme, HCL; Automated Insulin Delivery Systeme, AID, Diabetes-Apps) und den Zugang zu diesen technologischen Innovationen für Menschen mit Diabetes mellitus. Die Leitlinie wurde basierend auf aktueller wissenschaftlicher Evidenz erstellt.
Identifiants
pubmed: 37101025
doi: 10.1007/s00508-023-02165-9
pii: 10.1007/s00508-023-02165-9
pmc: PMC10132921
doi:
Substances chimiques
Insulin
0
Blood Glucose
0
Hypoglycemic Agents
0
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
53-61Informations de copyright
© 2023. The Author(s).
Références
Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765–74.
doi: 10.1111/j.1464-5491.2008.02486.x
pubmed: 18644063
Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(5):336–47.
doi: 10.7326/0003-4819-157-5-201209040-00508
pubmed: 22777524
Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51(6):941–51.
doi: 10.1007/s00125-008-0974-3
pubmed: 18351320
Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009;94(3):729–40.
doi: 10.1210/jc.2008-1415
pubmed: 19088167
Pańkowska E, Błazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10(1):52–8.
doi: 10.1111/j.1399-5448.2008.00440.x
pubmed: 18761648
Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2012;1:Cd8101.
pubmed: 22258980
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20.
doi: 10.1056/NEJMoa1002853
pubmed: 20587585
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603.
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–40.
doi: 10.2337/dc17-1600
pubmed: 29162583
pmcid: 6467165
Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–32.
doi: 10.1056/NEJMoa1303576
pubmed: 23789889
Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, Ludwig B, Nørgaard K, Pettus J, Renard E, Skyler JS, Snoek FJ, Weinstock RS, Peters AL. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609–52.
doi: 10.1007/s00125-021-05568-3
pubmed: 34590174
pmcid: 8481000
van den Boom L, Karges B, Auzanneau M, Rami-Merhar B, Lilienthal E, von Sengbusch S, et al. Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care. 2019;42(11):2050–6.
doi: 10.2337/dc19-0345
pubmed: 31488568
Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358–66.
doi: 10.1001/jama.2017.13994
pubmed: 29049584
pmcid: 5818842
Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310(12):1240–7.
doi: 10.1001/jama.2013.277818
pubmed: 24065010
Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: A randomized controlled trial. Diabetes Care. 2017;40(6):764–70.
doi: 10.2337/dc16-2584
pubmed: 28351897
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12.
doi: 10.1016/S2213-8587(17)30167-5
pubmed: 28533136
Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018;361:k1310.
doi: 10.1136/bmj.k1310
pubmed: 29669716
pmcid: 5902803
Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–8.
doi: 10.1001/jama.2016.11708
pubmed: 27629148
Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018;392(10155):1321–9.
doi: 10.1016/S0140-6736(18)31947-0
pubmed: 30292578
pmcid: 6182127
Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836–45.
doi: 10.1056/NEJMoa2004736
pubmed: 32846062
pmcid: 7920146
Amadou C, Franc S, Benhamou PY, Lablanche S, Huneker E, Charpentier G, et al. Diabeloop DBLG1 closed-loop system enables patients with type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events: 6‑month follow-up. Diabetes Care. 2021;44(3):844–6.
doi: 10.2337/dc20-1809
pubmed: 33431420
Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, Asztalos E, Barrett JFR, Sanchez JJ, de Leiva A, Hod M, Jovanovic L, Keely E, McManus R, Hutton EK, Meek CL, Stewart ZA, Wysocki T, O’Brien R, Ruedy K, Kollman C, Tomlinson G, Murphy HR. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347–59. https://doi.org/10.1016/S0140-6736(17)32400-5 .
doi: 10.1016/S0140-6736(17)32400-5
pubmed: 28923465
pmcid: 5713979
Feig DS, Corcoy R, Donovan LE, Murphy KE, Barrett JFR, Sanchez JJ, Wysocki T, Ruedy K, Kollman C, Tomlinson G, Murphy HR. Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial. Diabetes Care. 2018;41(12):2471–9. https://doi.org/10.2337/dc18-1437 .
doi: 10.2337/dc18-1437
pubmed: 30327362
Yamamoto JM, Murphy HR. Benefits of real-time continuous glucose monitoring in pregnancy. Diabetes Technol Ther. 2021;23(S1):S8–S14. https://doi.org/10.1089/dia.2020.0667 .
doi: 10.1089/dia.2020.0667
pubmed: 33512267
Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;61(3):539–50. https://doi.org/10.1007/s00125-017-4527-5 .
doi: 10.1007/s00125-017-4527-5
pubmed: 29273897
Yu F, Lv L, Liang Z, et al. Continuous glucose monitoring effects on maternal glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus: a prospective cohort study. J Clin Endocrinol Metab. 2014;99(12):4674–82.
doi: 10.1210/jc.2013-4332
pubmed: 25057872
Wei Q, Sun Z, Yang Y, Yu H, Ding H, Wang S. Effect of a CGMS and SMBG on maternal and neonatal outcomes in gestational diabetes mellitus: a randomized controlled trial. Sci Rep. 2016;6:19920.
doi: 10.1038/srep19920
pubmed: 26814139
pmcid: 4728693
Biester T, Dovc K, Chobot A, Tauschmann M, Kapellen T. Individualization of diabetes treatment by automated insulin delivery. Monatsschr Kinderheilkd. 2021;169(10):902–911. https://doi.org/10.1007/s00112-021-01239-0 .
doi: 10.1007/s00112-021-01239-0
pubmed: 34276070
pmcid: 8276231
Lane AS, Mlynarczyk MA, de Veciana M, Green LM, Baraki DI, Abuhamad AZ. Real-time continuous glucose monitoring in gestational diabetes: a randomized controlled trial. Am J Perinatol. 2019;36(9):891–7.
doi: 10.1055/s-0039-1678733
pubmed: 30818406
Karges B, et al. Association of insulin pumps therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358–66.
doi: 10.1001/jama.2017.13994
pubmed: 29049584
pmcid: 5818842
Rawshani A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Eng J Med. 2017;376(15):1407–18. https://doi.org/10.1056/NEJMoa1608664 .
doi: 10.1056/NEJMoa1608664
Ware J, et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med. 2022;386(3):209–19. https://doi.org/10.1056/NEJMoa2111673.PMID: .
doi: 10.1056/NEJMoa2111673.PMID:
pubmed: 35045227
Hofer SE, et al. Tracking of metabolic control from childhood to young adulthood in type 1 diabetes. J Pediatr. 2014;165(5):956–61.
doi: 10.1016/j.jpeds.2014.07.001
pubmed: 25151197
Samuelsson U, Steineck I, Gubbjornsdottir S. A high mean-HbA1c value 3–15 months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood—a pilot study using two nation-wide population based quality registries. Pediatr Diabetes. 2014;15:229–35.
doi: 10.1111/pedi.12085
pubmed: 24119008
Mazarello Paes V, Barrett JK, Taylor-Robinson DC, Chesters H, Charalampopoulos D, Dunger DB, Viner RM, Stephenson TJ. Effect of early glycemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: Systematic review and meta-analysis. Pediatr Diabetes. 2019;20:494–509.
pubmed: 30932298
pmcid: 6701989
Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, McGill JB, Aleppo G, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Buse JB, Price D, Bergenstal RM. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262–72. https://doi.org/10.1001/jama.2021.7444 .
doi: 10.1001/jama.2021.7444
pubmed: 34077499
Krakauer M, Botero JF, Lavalle-González FJ, Proietti A, Barbieri DE. A review of flash glucose monitoring in type 2 diabetes. Diabetol Metab Syndr. 2021;13(1):42–9. https://doi.org/10.1186/s13098-021-00654-3 .
doi: 10.1186/s13098-021-00654-3
pubmed: 33836819
pmcid: 8035716
Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–74. https://doi.org/10.7326/M16-2855 .
doi: 10.7326/M16-2855
pubmed: 28828487
Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73. https://doi.org/10.1007/s13300-016-0223-6 .
doi: 10.1007/s13300-016-0223-6
pubmed: 28000140
Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35(1):32–8. https://doi.org/10.2337/dc11-1438 .
doi: 10.2337/dc11-1438
pubmed: 22100963
Taylor PJ, Thompson CH, Brinkworth GD. Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: A narrative review. J Diabetes Investig. 2018;9(4):713–25. https://doi.org/10.1111/jdi.12807 .
doi: 10.1111/jdi.12807
pubmed: 29380542
pmcid: 6031515
Pickup JC, et al. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and Meta-regression of randomized controlled trials. Diabetes Care. 2017; https://doi.org/10.2337/dc16-2201 .
doi: 10.2337/dc16-2201
pubmed: 28428322
Werzowa JM, Säemann MD, Mohl A, Bergmann M, Kaltenecker CC, Brozek W, Thomas A, Haidinger M, Antlanger M, Kovarik JJ, Kopecky C, Song PXK, Budde K, Pascual J, Hecking M. A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation. PLoS ONE. 2018;13(3):e193569. https://doi.org/10.1371/journal.pone.0193569 .
doi: 10.1371/journal.pone.0193569
pubmed: 29518094
pmcid: 5843249
Marks BE, Kilberg MJ, Aliaj E, Fredkin K, Hudson J, Riva D, Román C, Kelly A, Putman MS. Perceptions of diabetes technology use in cystic fibrosis-related diabetes management. Diabetes Technol Ther. 2021;23(11):753–9. https://doi.org/10.1089/dia.2021.0201 .
doi: 10.1089/dia.2021.0201
pubmed: 34185606
Toner A, McCloy A, Dyce P, Nazareth D, Frost F. Continuous glucose monitoring systems for monitoring cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2021;11(11):CD13755. https://doi.org/10.1002/14651858.CD013755.pub2 .
doi: 10.1002/14651858.CD013755.pub2
pubmed: 34844283
Chan CL, Ode KL, Granados A, Moheet A, Moran A, Hameed S. Continuous glucose monitoring in cystic fibrosis—A practical guide. J Cyst Fibros. 2019;18(Suppl 2):S25–S31. https://doi.org/10.1016/j.jcf.2019.08.025 .
doi: 10.1016/j.jcf.2019.08.025
pubmed: 31679725
Sarteau AC, Souris KJ, Wang J, Ramadan AA, Addala A, Bowlby D, et al. Changes to care delivery at nine international pediatric diabetes clinics in response to the COVID-19 global pandemic. Pediatr Diabetes. 2021;22(3):463–8.
doi: 10.1111/pedi.13180
pubmed: 33470020
pmcid: 8013674
Wilmot EG, Lumb A, Hammond P, Murphy HR, Scott E, Gibb FW, et al. Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic. Diabet Med. 2021;38(1):e14433.
doi: 10.1111/dme.14433
pubmed: 33073388
American Diabetes Association. 7. Diabetes technology. Diabetes Care. 2021;44(Suppl 1):S85–S99.
doi: 10.2337/dc21-S007
Bergis D, Ehrmann D, Albrecht C, Haak T, Kulzer B, Hermanns N. Comparison of the efficacy of an education program for people with diabetes and insulin pump treatment (INPUT) in a randomized controlled trial setting and the effectiveness in a routine care setting: Results of a comparative effectiveness study. Patient Educ Couns. 2019;102(10):1868–74.
doi: 10.1016/j.pec.2019.04.021
pubmed: 31031097
Schlüter S, Freckmann G, Heinemann L, Wintergerst P, Lange K. Evaluation of the SPECTRUM training programme for real-time continuous glucose monitoring: A real-world multicentre prospective study in 120 adults with type 1 diabetes. Diabet Med. 2021;38(2):e14467.
doi: 10.1111/dme.14467
pubmed: 33230860
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449–2446.
doi: 10.1016/S0140-6736(18)31320-5
pubmed: 29916386
pmcid: 6661119